Abstract: The present disclosure provides the vector constructs comprising (a) a polynucleotide comprising a promoter operably linked to a nucleic acid of interest; (b) a first terminal repeat and a second terminal repeat; and (c) a backbone polynucleotide comprising a nucleic acid sequence that modulates a Toll-like receptor (TLR). Some aspects of the disclosure are related to methods for packaging the nucleic acid of interest and the nucleic acid sequence that modulates the TLR in an AAV particle, and some aspects are related to methods of modulating an immune response in a subject, comprising administering to said subject an effective amount of such AAV particles.

Abstract: The present disclosure provides gene therapy expression constructs comprising a nucleic acid encoding a therapeutic anti-TNFalpha antibody (e.g., a monoclonal antibody) or an antigen binding fragment thereof, delivery vectors (e.g., viral vectors) comprising the same, compositions comprising the same, and methods of using the same (e.g., to treat ocular diseases or disorders). Some aspects of the disclosure are directed to a recombinant adeno-viral vector (rAAV) delivery comprising an AAV particle (e.g., AAV2) and a nucleic acid encoding a therapeutic anti-TNFalpha antibody (e.g., a monoclonal antibody) or an antigen binding fragment thereof.

Abstract: The present disclosure provides the gene therapy compositions comprising vectors (e.g., viral vectors) suitable for delivery of nucleic acids encoding immunomodulatory proteins or functional fragments thereof, and methods of using the same. Certain aspects of the disclosure are directed to an adeno-viral vector (AAV) delivery of nucleic acids encoding two or more immunomodulatory proteins or functional fragments thereof to a tumor.